HAIKOU, China, Aug. 30, 2024 /PRNewswire/ — JX Luxventure Limited (Nasdaq: JXJT) (the “Company”), a technology company engages in integrated tourism services, including tourism, duty-free cross-border goods, and comprehensive e-commerce technology solutions, today announced that, on August 29, 2024, the Company has hired Mr. Zhang Chun Sheng as Director of Marketing.
Mr. Zhang Chun Sheng has over 15 years of experience in brand promotion and marketing and is a seasoned expert in this area. He previously held a senior role at Xunlei Limited (NASDAQ: XNET), where he played a crucial part in driving the company’s success.
Ms. Sun “Ice” Lei, Chief Executive Officer of the Company commented: “We are excited that Mr. Zhang joined our company. This confirms his confidence in our management and company. I look forward to collaborating with him to elevate the Luxventure brand and deepen our partnerships with major corporations. His expertise will be invaluable as we continue to expand our market presence and deliver exceptional value to our customers.”
About JX Luxventure Limited
Headquartered in Haikou, China, JX Luxventure Limited is a service provider delivering comprehensive solutions to global elite families. Its business includes integrated tourism services, including airfare, duty-free cross-border merchandise, and comprehensive e-commerce technology solutions. To learn more about the Company, please visit its corporate website at https://www.jxluxventure.com/en/.
Safe Harbor Statement
This press release may contain certain “forward-looking statements” relating to the business of JX Luxventure Limited, and its subsidiary companies. All statements, other than statements of historical fact included herein, are “forward-looking statements” in nature within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements due to a variety of factors, including those discussed in the Company’s annual and current reports filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.


Đề xuất
Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026
Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States
electroCore to Present at the Market Movers Investor Summit on May 5, 2026
Proxygen Expands Platform Beyond Degradation to Build Next-Generation Induced Proximity Therapeutics
Novo Nordisk to present new data on Wegovy®, women with obesity and next-generation weight loss treatments at European Congress on Obesity
Ping An Reports Steady 7.6% Growth in Operating Profit Attributable to Shareholders of the Parent Company in Q1 2026, Life & Health NBV Increases 20.8% YoY